TransMedics Group, Inc. (TMDX)
- Previous Close
89.25 - Open
90.00 - Bid 91.92 x 200
- Ask 92.17 x 100
- Day's Range
89.99 - 92.90 - 52 Week Range
36.42 - 99.63 - Volume
594,489 - Avg. Volume
741,757 - Market Cap (intraday)
3.025B - Beta (5Y Monthly) 1.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.77 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
99.40
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
www.transmedics.comRecent News: TMDX
Performance Overview: TMDX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMDX
Valuation Measures
Market Cap
3.02B
Enterprise Value
3.15B
Trailing P/E
--
Forward P/E
250.00
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.39
Price/Book (mrq)
22.05
Enterprise Value/Revenue
13.02
Enterprise Value/EBITDA
-408.42
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.36%
Return on Assets (ttm)
0.06%
Return on Equity (ttm)
-15.42%
Revenue (ttm)
241.62M
Net Income Avi to Common (ttm)
-25.03M
Diluted EPS (ttm)
-0.77
Balance Sheet and Cash Flow
Total Cash (mrq)
394.81M
Total Debt/Equity (mrq)
376.05%
Levered Free Cash Flow (ttm)
-191.58M